1
|
Bertog SC, Sievert K, Grunwald IQ, Sharma A, Hornung M, Kühn AL, Vaskelyte L, Hofmann I, Gafoor S, Reinartz M, Matic P, Sievert H. Acute Stroke Intervention. Interv Cardiol 2022. [DOI: 10.1002/9781119697367.ch71] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
2
|
Hahn RT, Kodali S, Fam N, Bapat V, Bartus K, Rodés-Cabau J, Dagenais F, Estevez-Loureiro R, Forteza A, Kapadia S, Latib A, Maisano F, McCarthy P, Navia J, Ong G, Peterson M, Petrossian G, Pozzoli A, Reinartz M, Ricciardi MJ, Robinson N, Sievert H, Taramasso M, Agarwal V, Bédard E, Tarantini G, Colli A. Early Multinational Experience of Transcatheter Tricuspid Valve Replacement for Treating Severe Tricuspid Regurgitation. JACC Cardiovasc Interv 2021; 13:2482-2493. [PMID: 33153565 DOI: 10.1016/j.jcin.2020.07.008] [Citation(s) in RCA: 61] [Impact Index Per Article: 20.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Revised: 07/01/2020] [Accepted: 07/07/2020] [Indexed: 11/29/2022]
Abstract
OBJECTIVES The aim of this registry was to evaluate the feasibility and safety of transcatheter tricuspid valve implantation (TTVI) in patients with extreme surgical risk. BACKGROUND Isolated tricuspid regurgitation (TR) surgery is associated with high in-hospital mortality. METHODS Thirty consecutive patients (mean age 75 ± 10 years; 56% women) from 10 institutions, with symptomatic functional TR, had institutional and notified body approval for compassionate use of the GATE TTVI system. Baseline, discharge, and 30-day follow-up echocardiographic data and procedural, in-hospital, and follow-up clinical outcomes were collected. RESULTS At baseline, all patients had multiple comorbidities, severe or greater TR, and reduced baseline right ventricular function. Technical success was achieved in 26 of 30 patients (87%). Device malpositioning occurred in 4 patients, with conversion to open heart surgery in 2 (5%). Of those who received the device, 100% had reductions in TR of ≥1, and 75% experienced reductions of ≥2 grades, resulting in 18 of 24 of patients (76%) with mild or less TR at discharge. All patients had mild or less central TR. There was continued improvement in TR grade between discharge and 30 days in 15 of 19 patients (79%). In-hospital mortality was 10%. At mean follow-up of 127 ± 82 days, 4 patients (13%) had died. Of patients alive at follow-up, 62% were in New York Heart Association functional class I or II, with no late device-related adverse events. CONCLUSIONS Compassionate treatment of severe, symptomatic functional TR using a first-generation TTVI device is associated with significant reduction in TR and improvement in functional status with acceptable in-hospital mortality. Further studies are needed to determine the appropriate patient population and long-term outcomes with TTVI therapy.
Collapse
Affiliation(s)
- Rebecca T Hahn
- Columbia University Medical Center/NewYork-Presbyterian Hospital, New York, New York.
| | - Susheel Kodali
- Columbia University Medical Center/NewYork-Presbyterian Hospital, New York, New York
| | - Neil Fam
- Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
| | - Vinayak Bapat
- Columbia University Medical Center/NewYork-Presbyterian Hospital, New York, New York
| | - Krzysztof Bartus
- Department of Cardiovascular Surgery and Transplantology, Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland
| | - Josep Rodés-Cabau
- Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec, Quebec, Canada
| | - Francois Dagenais
- Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec, Quebec, Canada
| | | | | | | | | | | | - Patrick McCarthy
- Northwestern University Feinberg School of Medicine, Northwestern Medicine, Chicago, Illinois
| | - Jose Navia
- Cleveland Clinic Foundation, Cleveland, Ohio
| | - Geraldine Ong
- Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
| | - Mark Peterson
- Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
| | - George Petrossian
- NorthShore Cardiovascular Institute, NorthShore University Health System, Evanston, Illinois
| | | | - Markus Reinartz
- St. Francis Hospital, The Heart Center, Catholic Health Services, Roslyn, New York
| | - Mark J Ricciardi
- NorthShore Cardiovascular Institute, NorthShore University Health System, Evanston, Illinois
| | - Newell Robinson
- St. Francis Hospital, The Heart Center, Catholic Health Services, Roslyn, New York
| | | | | | | | - Elisabeth Bédard
- Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec, Quebec, Canada
| | - Giuseppe Tarantini
- Department of Cardiology, Thoracic and Vascular Sciences, University of Padova Medical School, Padova, Italy
| | - Andrea Colli
- Department of Surgical, Medical and Molecular Pathology and Critical Care, University of Pisa, Pisa, Italy
| |
Collapse
|
3
|
Sievert K, Yu J, Bertog S, Hornung M, von Bardeleben RS, Gafoor S, Reinartz M, Matic P, Hofmann I, Grunwald I, Schnelle N, Sievert H. Post-Market Clinical Follow-Up With the Patent Foramen Ovale Closure Device IrisFIT (Lifetech) in Patients With Stroke, Transient Ischemic Attack, or Other Thromboembolic Events. Cardiovasc Revasc Med 2020; 30:72-75. [PMID: 33097460 DOI: 10.1016/j.carrev.2020.09.031] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2020] [Revised: 09/14/2020] [Accepted: 09/21/2020] [Indexed: 10/23/2022]
Abstract
BACKGROUND A patent foramen ovale (PFO) has been associated with embolic strokes and transient ischemic attacks (TIAs). Catheter closure of PFO is effective in preventing recurrent events. Residual shunts and procedure or device related complications can occur, including atrial fibrillation and thrombus formation. This study examines the initial experience with a new PFO closure device, the IrisFIT PFO-Occluder (Lifetech Scientific, Shenzhen, China). METHODS 95 patients with indications for PFO closure underwent percutaneous closure with the IrisFIT PFO-Occluder. The primary endpoint was the rate of accurate device placement with no/small residual shunt at 3 or 6 months follow-up. All patients underwent transoesophageal echocardiography (TEE) after 1 to 6 months. In case of a residual shunt, an additional TEE was performed after 12 months. Clinical follow-up was performed up to a mean of 33.1 ± 3.6 months. RESULTS The device was successfully implanted in 95 (100%) patients with no relevant procedural complications. At final TEE follow-up (7.6 ± 3.9 months) the effective closure rate was 96.8% with 1 moderate and 2 large residual shunts. There were 8 cases of new onset atrial fibrillation and 2 TIAs. There were no cases of device embolization or erosion. CONCLUSION The IrisFIT occluder is a new PFO closure device with several advantages compared to other devices. In this small study cohort, technical success rate, closure rate and adverse event rate were comparable to other devices. The rate of new onset atrial fibrillation was higher in comparison to other studies and warrants further investigation.
Collapse
Affiliation(s)
| | - Jiangtao Yu
- Helmut-G.-Walther-Klinikum, Lichtenfels, Germany
| | | | | | - Ralph Stephan von Bardeleben
- Medizinische Klinik - Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsmedizin Mainz, Mainz, Germany
| | | | | | | | | | - Iris Grunwald
- CardioVascular Center Frankfurt, Frankfurt, Germany; Anglia Ruskin University, Chelmsford, United Kingdom
| | - Nalan Schnelle
- CardioVascular Center Frankfurt, Frankfurt, Germany; Medizinische Klinik - Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsmedizin Mainz, Mainz, Germany
| | - Horst Sievert
- CardioVascular Center Frankfurt, Frankfurt, Germany; Anglia Ruskin University, Chelmsford, United Kingdom.
| |
Collapse
|
4
|
Goncalves CR, Bertog S, Tholakanahalli V, Römer A, Hofmann I, Reinartz M, Gafoor S, Sievert K, Schnelle N, Grunwald I, Sievert H. Permanent Pacemaker Lead Insertion Connected to an External Pacemaker Generator for Temporary Pacing After Transcatheter Aortic Valve Implantation. Cardiovascular Revascularization Medicine 2020; 21:726-729. [DOI: 10.1016/j.carrev.2020.02.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2019] [Revised: 01/05/2020] [Accepted: 02/04/2020] [Indexed: 10/25/2022]
|
5
|
Hornung M, Bertog SC, Gafoor S, Reinartz M, Vaskelyte L, Hofmann I, Sievert K, Matic P, Grunwald I, Sievert H. The IrisFIT Patent Foramen Ovale Closure Device in Patients With History of Cryptogenic Embolization. J Invasive Cardiol 2019; 31:319-324. [PMID: 31522140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
BACKGROUND The aim of this study was to assess safety, efficacy, and clinical outcome of the IrisFIT PFO Closure System (Lifetech Scientific) for transcatheter closure of patent foramen ovale (PFO) in patients with a history of cryptogenic stroke, transient ischemic attack (TIA), or peripheral embolization. PATIENTS AND METHODS We report the results of 60 consecutive patients undergoing PFO closure with the IrisFIT occluder for secondary prevention of paradoxical embolization. All cases were analyzed for periprocedural and device-related adverse events up to 12 months after implantation. In addition, the patients were evaluated for complete defect closure with transesophageal echocardiography (TEE) after 1 month, 6 months, and (if indicated) 12 months. Mean patient age was 53 ± 14 years and 37 patients (62%) were males. All patients had a history of at least 1 cryptogenic stroke, TIA, or peripheral embolization. RESULTS Technical success was achieved in all 60 procedures. The mean procedure time was 28 ± 11 minutes. There were no periprocedural or device-related complications up to 12 months after the implant. Successful defect closure at 6 months post device implantation was achieved in 56 cases (93.3%). Within 12 months of follow-up, 2 patients had recurrent TIAs, both with complete PFO sealing at the last TEE prior to the event. CONCLUSION The IrisFIT PFO Closure System can be used safely and with high technical success for secondary prevention of cryptogenic stroke or peripheral embolization.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Horst Sievert
- CardioVascular Center Frankfurt CVC, Seckbacher Landstrasse 65, 60389 Frankfurt, Germany.
| |
Collapse
|
6
|
Vaskelyte L, Bertog S, Hofmann I, Jovanović B, Reinartz M, Matić P, Gafoor S, Sievert K, Sievert H. A case of mislabeled textbooks: misnomer of the traditional "bicaval" view. Cardiovasc Diagn Ther 2018; 8:508-511. [PMID: 30214866 DOI: 10.21037/cdt.2018.05.01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Since the early beginning of the transesophageal echocardiography (TEE) era, standardized tomographic views describing cardiac key structures have been provided. They have become the basis of TEE and have not been modified for decades. During our recent structural interventional cases, it has come to our attention that the structure frequently labeled "inferior vena cava" in textbooks and journal articles illustrating the bicaval TEE view is, in fact, the coronary sinus. Our manuscript illustrates our observation.
Collapse
Affiliation(s)
| | - Stefan Bertog
- CardioVascular Center Frankfurt, Frankfurt, Germany.,Minneapolis Veterans Affairs Medical Center, Minneapolis, USA
| | | | | | | | | | - Sameer Gafoor
- CardioVascular Center Frankfurt, Frankfurt, Germany.,Swedish Heart and Vascular Institute, Seattle, USA
| | | | | |
Collapse
|
7
|
Bertog SC, Grunwald IQ, Kühn AL, Vaskelyte L, Hofmann I, Gafoor S, Reinartz M, Matic P, Sievert H. Acute Stroke Intervention. Interv Cardiol 2016. [DOI: 10.1002/9781118983652.ch68] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Affiliation(s)
| | - Iris Q. Grunwald
- Post Graduate Medical Institute; Anglia Ruskin University; Chelmsford UK
- Southend University Hospital; Southend-on-Sea UK
| | - Anna Luisa Kühn
- Department of Radiology; University of Massachusetts Medical School; Worcester MA USA
| | | | | | - Sameer Gafoor
- CardioVascular Center Frankfurt; Frankfurt Germany
- Swedish Medical Center; Seattle WA USA
| | - Markus Reinartz
- CardioVascular Center Frankfurt; Frankfurt Germany
- Herz-Jesu-Krankenhaus; Dernbach Germany
| | | | - Horst Sievert
- CardioVascular Center Frankfurt; Frankfurt Germany
- Anglia Ruskin University; Chelmsford UK
| |
Collapse
|
8
|
Siebel A, Markewitz A, Doll N, Bärsch V, Reinartz M, Oswald B, Bimmel D, Meyer A, Weimar T, Walther T, Burger H, Ziegelhoeffer T. Intraoperative Defibrillation Testing Should Not Be Generally Abandoned for All ICD Procedures—A Multicenter Study on 4,572 Consecutive Patients. Thorac Cardiovasc Surg 2016; 64:679-687. [DOI: 10.1055/s-0036-1583767] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
| | - Andreas Markewitz
- Departmentof XVII –Cardiovascular Surgery, Bundeswehrzentralkrankenhaus Koblenz, Koblenz, Rheinland-Pfalz, Germany
| | - Nicolas Doll
- Department of Cardiac Surgery, Sana HerzchirurgischeKlinik Stuttgart GmbH, Stuttgart, Baden-Württemberg, Germany
| | - Volker Bärsch
- Department of Cardiology, St. MarienKrankenhaus, Siegen, Germany
| | - Markus Reinartz
- Department of Cardiology, KatholischesKlinikum Koblenz Montabaur, Koblenz, Rheinland-Pfalz, Germany
| | - Brigitte Oswald
- Department of Cardiovascular Surgery, Universitatsklinikum Dusseldorf, Dusseldorf, Nordrhein-Westfalen, Germany
| | - Dieter Bimmel
- Department of Cardiology, St. Marien Hospital, Bonn, Germany
| | - Alexander Meyer
- Department of Cardiac Surgery, Kerckhoff Klinik, Bad Nauheim, Germany
| | - Timo Weimar
- Department of Cardiac Surgery, Sana HerzchirurgischeKlinik Stuttgart GmbH, Stuttgart, Baden-Württemberg, Germany
| | - Thomas Walther
- Department of Cardiac Surgery, Kerckhoff Klinik, Bad Nauheim, Germany
| | - Heiko Burger
- Department of Cardiac Surgery, Kerckhoff Klinik, Bad Nauheim, Germany
| | | |
Collapse
|
9
|
Karim S, Lucas V, Verma A, Girgrah N, Ramee S, Castriota F, Micari A, Roscitano G, Spinelli F, Gafoor S, Haseeb A, Khan A, Franke J, Matic P, Reinartz M, Bertog S, Vaskelyte L, Hofmann I, Sievert H. How should I treat Budd-Chiari syndrome after liver transplantation with inferior vena cava occlusion? EUROINTERVENTION 2016; 12:124-8. [PMID: 27173874 DOI: 10.4244/eijv12i1a22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Affiliation(s)
- Saima Karim
- Department of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Piayda KD, Gafoor S, Bertog S, Doss M, Vaskelyte L, Matic P, Franke J, Hofmann I, Staiger N, Reinartz M, Sievert H. True First-Line Local-Anesthesia Only Protocol for Transfemoral TAVI. J Invasive Cardiol 2015; 27:501-508. [PMID: 26524203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
AIMS To evaluate the safety and feasibility of transcatheter aortic valve implantation (TAVI) via femoral access under local anesthesia only (without concomitant sedation) as the initial strategy. METHODS AND RESULTS Patients undergoing planned transfemoral TAVI without routine general anesthesia between May 2005 and December 2013 were identified. Baseline characteristics, procedural outcomes, and a 30-day clinical follow-up were obtained. A total of 215 patients underwent TAVI with local anesthesia only as the initial strategy (LA group). Of these patients, 40 (18.6%) received additional sedation (LAS group) during the procedure due to inadequate pain control or agitation and 7 patients (3.3%) underwent conversion to general anesthesia (GA group). TAVI was successfully performed in 211 cases (98.2%). When 30-day outcomes for patients requiring only local anesthesia were compared with patients requiring additional sedation, there was a significantly longer duration of Intensive Care Unit (ICU) stay in the group with additional sedation (LAS, 5.0 days [range, 3.0-6.0 days] vs LA 3 days [range, 2.0-5.0 days]; P=.02) and general anesthesia (GA 7.0 days [range, 2.5-18.0 days] vs LA 3 days [range, 2.0-5.0]; P=.04). CONCLUSION Our study suggests that TAVI with LA only as the initial strategy is a feasible alternative to GA, with potential benefit of this strategy over using routine concomitant sedation. LA only may be considered a primary option in many patients.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Horst Sievert
- CardioVascular Center Frankfurt, Seckbacher Landstrasse 65, 60389 Frankfurt, Germany.
| |
Collapse
|
11
|
Gafoor S, Heuer L, Schulz P, Matic P, Franke J, Bertog S, Reinartz M, Vaskelyte L, Hofmann I, Sievert H. “A bend in time”: Shaping the sheath facilitates left atrial appendage closure. Catheter Cardiovasc Interv 2015; 86:E224-8. [DOI: 10.1002/ccd.25996] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/05/2014] [Accepted: 04/04/2015] [Indexed: 11/08/2022]
Affiliation(s)
- Sameer Gafoor
- CardioVascular Center Frankfurt; Frankfurt Germany
- Swedish Medical Center; Seattle WA USA
| | - Luisa Heuer
- CardioVascular Center Frankfurt; Frankfurt Germany
| | | | | | - Jennifer Franke
- CardioVascular Center Frankfurt; Frankfurt Germany
- Department of Cardiology; University of Heidelberg; Heidelberg Germany
| | - Stefan Bertog
- CardioVascular Center Frankfurt; Frankfurt Germany
- Department of Cardiology; Veterans Affairs Hospital; Minneapolis Minnesota
| | | | | | | | | |
Collapse
|
12
|
Abstract
Heart failure is a growing epidemic, with more patients living longer and suffering from this disease. There is a growing segment of patients who have persistent symptoms despite pharmacologic therapy. In an era when transplants are rare, the need for devices and interventions that can assist ventricular function is paramount. This review goes through the devices used in heart failure, including left ventricular reconstruction, aortic counterpulsation, short-term mechanical circulatory support, long-term mechanical circulatory support, and right heart interventions.
Collapse
Affiliation(s)
- Sameer Gafoor
- CardioVascular Center Frankfurt (CVC), Frankfurt, Germany
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Schulz A, Krabatsch T, Reinartz M, Köln P, Hotz H. The Berlin Experience with the C-Pulse® Heart Assist System after 6 Months of Observation. Thorac Cardiovasc Surg 2015. [DOI: 10.1055/s-0035-1544270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
14
|
Schulz A, Hotz H, Reinartz M, Potapov E, Seidel M, Theres L, Bruch L, Schmitto J, Hetzer R, Krabatsch T. Preliminary Results from the C-Pulse® System European Multicenter Study. J Heart Lung Transplant 2014. [DOI: 10.1016/j.healun.2014.01.895] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
15
|
Murmann T, Carrillo-García C, Veit N, Courts C, Glassmann A, Janzen V, Madea B, Reinartz M, Harzen A, Nowak M, Perner S, Winter J, Probstmeier R. Staurosporine and extracellular matrix proteins mediate the conversion of small cell lung carcinoma cells into a neuron-like phenotype. PLoS One 2014; 9:e86910. [PMID: 24586258 PMCID: PMC3938400 DOI: 10.1371/journal.pone.0086910] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2013] [Accepted: 12/17/2013] [Indexed: 11/23/2022] Open
Abstract
Small cell lung carcinomas (SCLCs) represent highly aggressive tumors with an overall five-year survival rate in the range of 5 to 10%. Here, we show that four out of five SCLC cell lines reversibly develop a neuron-like phenotype on extracellular matrix constituents such as fibronectin, laminin or thrombospondin upon staurosporine treatment in an RGD/integrin-mediated manner. Neurite-like processes extend rapidly with an average speed of 10 µm per hour. Depending on the cell line, staurosporine treatment affects either cell cycle arrest in G2/M phase or induction of polyploidy. Neuron-like conversion, although not accompanied by alterations in the expression pattern of a panel of neuroendocrine genes, leads to changes in protein expression as determined by two-dimensional gel electrophoresis. It is likely that SCLC cells already harbour the complete molecular repertoire to convert into a neuron-like phenotype. More extensive studies are needed to evaluate whether the conversion potential of SCLC cells is suitable for therapeutic interventions.
Collapse
Affiliation(s)
- Tamara Murmann
- Neuro- and Tumor Cell Biology Group, Department of Nuclear Medicine, University Hospital of Bonn, Bonn, Germany
| | | | - Nadine Veit
- Neuro- and Tumor Cell Biology Group, Department of Nuclear Medicine, University Hospital of Bonn, Bonn, Germany
| | | | | | - Viktor Janzen
- Department of Hematology and Oncology, University Hospital of Bonn, Bonn, Germany
| | - Burkhard Madea
- Institute of Legal Medicine, University of Bonn, Bonn, Germany
| | - Markus Reinartz
- Oral Cell Biology Group, Department of Periodontology, Operative and Preventive Dentistry, Bonn, Germany
| | - Anne Harzen
- Proteomics Group, Max-Planck-Institute for Plant Breeding Research, Cologne, Germany
| | - Michael Nowak
- Department of Prostate Cancer Research, Institute of Pathology, University Hospital of Bonn, Bonn, Germany
| | - Sven Perner
- Department of Prostate Cancer Research, Institute of Pathology, University Hospital of Bonn, Bonn, Germany
| | - Jochen Winter
- Oral Cell Biology Group, Department of Periodontology, Operative and Preventive Dentistry, Bonn, Germany
| | - Rainer Probstmeier
- Neuro- and Tumor Cell Biology Group, Department of Nuclear Medicine, University Hospital of Bonn, Bonn, Germany
- * E-mail:
| |
Collapse
|
16
|
Ziegelhoeffer T, Siebel A, Markewitz A, Doll N, Bärsch V, Reinartz M, Oswald B, Bimmel D, Weimar T, Meyer A, Walther T, Burger H. Risk factors for intra-operative defibrillation testshock failure in a multivariante analysis of 4572 consecutive patients. Thorac Cardiovasc Surg 2014. [DOI: 10.1055/s-0034-1367172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
17
|
Hotz H, Schulz A, Krabatsch T, Reinartz M, Siniawski H, Delmo Walter E, Hetzer R. The Berlin experience with the first three C-Pulse® implants in Europe. Thorac Cardiovasc Surg 2014. [DOI: 10.1055/s-0034-1367364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
18
|
Ziegelhöffer T, Siebel A, Markewitz A, Doll N, Baersch V, Reinartz M, Osswald B, Bimmel D, Walther T, Burger H. Intraoperative ICD defibrillation testing has to be recommended according to multicenter data – final results. Thorac Cardiovasc Surg 2013. [DOI: 10.1055/s-0032-1332468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
19
|
Dommisch H, Reinartz M, Backhaus T, Deschner J, Chung W, Jepsen S. Antimicrobial responses of primary gingival cells toPorphyromonas gingivalis. J Clin Periodontol 2012; 39:913-22. [DOI: 10.1111/j.1600-051x.2012.01933.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/18/2012] [Indexed: 11/28/2022]
Affiliation(s)
| | | | | | | | - Whasun Chung
- Department of Oral Biology; University of Washington; Seattle; WA; USA
| | | |
Collapse
|
20
|
Hufbauer M, Lazić D, Reinartz M, Akgül B, Pfister H, Weissenborn SJ. Skin tumor formation in human papillomavirus 8 transgenic mice is associated with a deregulation of oncogenic miRNAs and their tumor suppressive targets. J Dermatol Sci 2011; 64:7-15. [DOI: 10.1016/j.jdermsci.2011.06.008] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2010] [Revised: 06/06/2011] [Accepted: 06/10/2011] [Indexed: 01/07/2023]
|
21
|
Schaefer AS, Richter GM, Dommisch H, Reinartz M, Nothnagel M, Noack B, Laine ML, Folwaczny M, Groessner-Schreiber B, Loos BG, Jepsen S, Schreiber S. CDKN2BAS is associated with periodontitis in different European populations and is activated by bacterial infection. J Med Genet 2010; 48:38-47. [DOI: 10.1136/jmg.2010.078998] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
22
|
Allam JP, Würtzen PA, Reinartz M, Winter J, Vrtala S, Chen KW, Valenta R, Wenghoefer M, Appel T, Gros E, Niederhagen B, Bieber T, Lund K, Novak N. Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta1 and IL-10-producing properties. J Allergy Clin Immunol 2010; 126:638-45.e1. [PMID: 20584546 DOI: 10.1016/j.jaci.2010.04.039] [Citation(s) in RCA: 103] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2009] [Revised: 03/26/2010] [Accepted: 04/27/2010] [Indexed: 12/12/2022]
Abstract
BACKGROUND Sublingual immunotherapy (SLIT) is safe and effective as treatment of allergic rhinitis and mild asthma. Oral mucosal Langerhans cells (oLCs) play a central role. However, little is known about allergen binding by oLCs during mucosal allergen resorption and its impact on oLC functions. OBJECTIVE Binding of Phl p 5 to oLCs was studied in a standardized ex vivo model to investigate mechanisms important for SLIT. METHODS Human oral mucosal biopsies were incubated with the grass pollen allergen Phl p 5. Migration, binding of Phl p 5, phenotype and cytokine production, and T-cell priming of Phl p 5-binding oLCs were analyzed. RESULTS Significant uptake required more than 5 minutes, and dose-dependent binding of Phl p 5 to oLCs was saturated at 100 microg/mL Phl p 5. Furthermore, Phl p 5 significantly increased the migratory capacity of oLCs but attenuated their maturation and strongly promoted the release of TGF-beta1 and IL-10 by oLCs themselves as well as by cocultured T cells. CONCLUSION Oral mucosal Langerhans cells bind Phlp5 in a dose-dependent and time-dependent manner, leading to an increased production of tolerogenic cytokines and an enhanced migratory capacity but decelerated maturation of oLCs.
Collapse
Affiliation(s)
- Jean-Pierre Allam
- Department of Dermatology and Allergy, University of Bonn, Bonn, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Abstract
Sulfide oxidation in the phototrophic purple sulfur bacterium Chromatium vinosum D (DSMZ 180(T)) was studied by insertional inactivation of the fccAB genes, which encode flavocytochrome c, a protein that exhibits sulfide dehydrogenase activity in vitro. Flavocytochrome c is located in the periplasmic space as shown by a PhoA fusion to the signal peptide of the hemoprotein subunit. The genotype of the flavocytochrome-c-deficient Chr. vinosum strain FD1 was verified by Southern hybridization and PCR, and the absence of flavocytochrome c in the mutant was proven at the protein level. The oxidation of thiosulfate and intracellular sulfur by the flavocytochrome-c-deficient mutant was comparable to that of the wild-type. Disruption of the fccAB genes did not have any significant effect on the sulfide-oxidizing ability of the cells, showing that flavocytochrome c is not essential for oxidation of sulfide to intracellular sulfur and indicating the presence of a distinct sulfide-oxidizing system. In accordance with these results, Chr. vinosum extracts catalyzed electron transfer from sulfide to externally added duroquinone, indicating the presence of the enzyme sulfide:quinone oxidoreductase (EC 1.8.5.-). Further investigations showed that the sulfide:quinone oxidoreductase activity was sensitive to heat and to quinone analogue inhibitors. The enzyme is strictly membrane-bound and is constitutively expressed. The presence of sulfide:quinone oxidoreductase points to a connection of sulfide oxidation to the membrane electron transport system at the level of the quinone pool in Chr. vinosum.
Collapse
Affiliation(s)
- M Reinartz
- Institut für Mikrobiologie & Biotechnologie, Rheinische Friedrich-Wilhelms-Universität Bonn, Meckenheimer Allee 168, D-53115 Bonn, Germany
| | | | | | | | | |
Collapse
|